COVID-19 to Substantially Increase the Demand for 3D Printing Medical Devices Market from Key End-use Industry Sectors Unveils Fact.MR

Mass technological transformation of the global healthcare industry has left key market participants struggling to traverse the complexities of medical and life sciences. Given the shifting dynamics of the global healthcare sector, pharma and biotech companies are taking measured efforts to improve patient outcomes in an effective manner, while keeping a careful watch on the bottom line.

The global 3D printing medical devices market is expected to exceed US$ 1,700 Mn in revenues by 2022-end, according to a recent research by Fact.MR. The global 3D printing medical devices market is poised to exhibit a high double-digit CAGR during 2017 to 2022. Introduction of 3D-printed tablets has paved new opportunities for 3D-printing technology, increasing its application across the pharmaceutical industry. Numerous collaborations have been witnessed worldwide, between academic institutions and major players in the market, who are investing heavily in R&D activities. 3D-printing technology has been revolutionizing the preclinical drug testing, making the testing on 3D-printed organs convenient, thereby resulting into the provision of a substitute for animal testing. This technology is also making it easy for surgeons to improve the complicated procedures’ success rate. The aforementioned factors are expected to augment demand for 3D printing medical devices in the years to come.

Potential of 3D-printing in transforming medical devices’ use to treat various diseases is impacting the healthcare sector, enabling construction of non-implantable and implantable medical devices, and cost-effective customizable medical devices. Rise in demand for medical devices that match a patient’s anatomy in orthopedic, and maxillofacial surgery is favoring expansion of medical 3D-printing industry. Facilitating surgeons in planning surgeries, 3D printing medical devices help in lowering operative risks encountered during complex procedures, reduce duration of anesthesia exposure, decrease risk of infection, enable patients in recovering faster, and dramatically reduce time of hospital stay. These factors might further impact the market growth over the forecast period.

For more insights, Request a Sample of 3D Printing Medical Devices Market Report https://www.factmr.com/connectus/sample?flag=S&rep_id=248

Market Taxonomy

By Product Type

  • 3D Printers
  • 3D Bio-Printers
  • Materials
  • Software & Services

By End User

  • Hospitals
  • Academic Institutes
  • Contract Research Organizations
  • Pharma and Biotech Companies

By Technology

  • Laser Beam Melting
  • Photo polymerization
  • Three-Dimensional Printing
  • Electron Beam Melting
  • Droplet Deposition

By Application

  • Implants
  • Tissue Engineering
  • External Wearable Devices

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/248/S

6 Key Estimations for Future of 3D printing medical devices market

  1. Followed by tissue engineering, implants will continue to be the most lucrative application of the 3D-printing medical devices, in terms of revenues. Sale of 3D-printing medical devices for application in building external wearable devices is estimated to exhibit a comparatively lower CAGR through 2022.
  2. Software & services are anticipated to remain preferred among products in the global market. Revenues from software & services are expected to account for more than one-third share of the market throughout the forecast period. In addition, sales of 3D-printing materials will exhibit the highest CAGR through 2022.
  3. Photo polymerization is projected to remain the largest adopted technology in the global market for 3D-printing medical devices, followed by the laser beam melting technology. In addition, sales of electron beam melting technology, and three-dimensional printing technology are expected to exhibit a similar CAGR through 2022.
  4. On the basis of end-users, hospitals will remain dominant in the market, with sales poised to exceed revenues worth US$ 1,000 Mn by 2022-end.
  5. Asia-Pacific excluding Japan (APEJ) will emerge as the fastest expanding market for 3D-printing medical devices during the forecast period. In terms of revenues, North America is expected to be the most lucrative region for growth of the market.
  6. The report profiles key players operating in the market, which include Cyfuse Biomedical K.K., Stratasys Ltd., SLM Solutions Group AG, Renishaw plc, Groupe Gorgé SA, Organovo Holdings, Inc., Materialise NV, EnvisionTEC GmbH, General Electric Company, Carbon, Inc., Biomedical Modeling Inc., and 3D Systems Corporation.

For comprehensive insights on this market adoption, ask an analyst here https://www.factmr.com/connectus/sample?flag=AE&rep_id=248

Explore Fact.MR’s Coverage on the Healthcare Domain

Electrosurgery Devices Market: A recent study by Fact.MR on the Electrosurgery Devices Market offers a 10-year forecast analysis for the period 2017 to 2022. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Coatings for Medical Devices Market: Fact.MR’s extensive coverage on the Coatings for Medical Devices Market offers in-depth insights about the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

ENT Medical Devices Market: The ENT Medical Devices Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: sales@factmr.com

Visit Our Website: https://www.factmr.com

SourceFACT.MR

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version